Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC

PURPOSEPlasma circulating tumor DNA (ctDNA) analysis is routine for genotyping of advanced non–small-cell lung cancer (NSCLC); however, early response assessment using plasma ctDNA has yet to be we...